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Keystone Symposium: Banff Springs, Canada, February 2012
TheJointKeystone Symposiaon Cancer andMetabolism and
Advances in Hypoxic Signaling: From Bench to Bedside were
held in Banff, Alberta, Canada from 12 to 17 February 2012.
Drs. Reuben Shaw and David Sabatini organized the Cancer
and Metabolism section, and Drs. Volker Haase, Cormac
Taylor, Johanna Myllyharju and Paul Schumacker organized
the Advances in Hypoxic Signaling section. Accumulating
data illustrate that both hypoxia and rewired metabolism
inﬂuence cancer biology. Indeed, these phenomena are
tightly coupled, and a joint meeting was held to foster
interdisciplinary interactions and enhance our understanding
ofthesetwoprocessesinneoplasticdisease.Inthisreport,we
highlight the major themes of the conference paying particular
attention to areas of intersection between hypoxia and
metabolism in cancer.
One opening keynote address was delivered by Craig
Thompson (Memorial Sloan-Kettering, USA), in which he
provided a comprehensive perspective on the current thinking
around how altered metabolism supports cancer cell growth
and survival, and discussed areas likely to be important for
future discovery. In particular, Thompson highlighted the
essential roles of glucose and glutamine in cell growth,
how glucose- and glutamine-consuming processes are
rewired in cancer and how this rewiring facilitates anabolic
metabolism. These topics were at the core of many of the
metabolism presentations that described in detail how
some metabolic alterations contribute to the properties of
transformed cells.
The other keynote address was delivered by Peter Ratcliffe
(University of Oxford, UK), in which he provided a historical
perspective on the progress of how signaling events sense
oxygen. Mammals have evolved multiple acute and long-term
adaptive responses to low oxygen levels (hypoxia). This
response prevents a disparity in ATP utilization and produc-
tion that would otherwise result in a bioenergetic collapse
when oxygen level is low. Multiple effectors have been
proposed to mediate the response to hypoxia including prolyl
hydroxylases,AMPK,NADPHoxidasesandthemitochondrial
complex III. Currently, however, the precise mechanism by
which oxygen is sensed in various physiological contexts
remains unknown. Indeed, this was an active point of debate,
with Peter Ratcliffe favoring the prolyl hydroxylase PHD2 as
the primary cellular oxygen sensor.
Cancer and Metabolism
Anabolic glucose metabolism and the Warburg effect.
Nearly a century ago, Warburg noted that cancer tissues take
up glucose in excess than most normal tissues and secrete
much of the carbon as lactate. Recently, headway has been
made toward determining how the enhanced glucose
conversion to lactate occurs and contributes to cell prolifera-
tion and survival. Heather Christofk (University of California,
Los Angeles, USA) and John Cleveland (the Scripps
Research Institute, USA) described a role for the lactate/
pyruvate transporter MCT-1 in carbon secretion, and
suggested that blocking lactate or pyruvate transport may
be a strategy to target glucose metabolism in cancer cells.
Kun-Liang Guan (University of California, San Diego, USA)
described a novel feedback loop to control glucose metabo-
lism in highly glycolytic cells. Speciﬁcally, he discussed how
glucose-derived acetyl-CoA can be used as a substrate to
modify two enzymes involved in glucose metabolism,
pyruvate kinase M2 (PKM2) and phosphoenolpyruvate
carboxylase (PEPCK). In both cases, acetylation leads to
protein degradation and decreased glycolysis and gluconeo-
genesis, respectively. Data presented from Matthew Vander
Heiden’s laboratory (Koch Institute/MIT, USA) illustrated that
loss of pyruvate kinase activity can accelerate tumor growth,
suggesting that the regulation of glycolysis may be more
complex than previously appreciated. Almut Schulze
(London Research Institute, UK) discussed a novel
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glucose metabolism and Jeffrey Rathmell (Duke University,
USA) discussed parallels between glucose metabolism
in cancer cells and lymphocytes that suggest many
of these phenotypes could be a feature of rapidly dividing
cells.
Glutamine addiction. Cancer cells also consume glutamine
to support proliferation and survival. Alfredo Csibi (Harvard
Medical School, USA) described how mTORC1 promotes
glutamine utilization by indirectly regulating the activity of
glutamate dehydrogenase. This work united two major
themes at the meeting, mTOR signaling and glutamine
metabolism, highlighting the interconnectedness of signal
transduction and metabolic regulation. Richard Cerione
(Cornell University, USA) described a small molecule
inhibitor of glutaminase that can be used to target gluta-
mine-addicted cancer cells. Christian Metallo (University
of California, San Diego, USA), Andrew Mullen (University
of Texas Southwestern Medical School, USA) and Patrick
Ward (Memorial Sloan-Kettering, USA) presented data
demonstrating that the carbon skeleton of glutamine can be
incorporated into newly synthesized lipids. This contribution
of glutamine to lipid synthesis was most pronounced in
hypoxia or when the mitochondrial electron transport chain
was compromised.
Signal transduction and metabolism. The protein kinases
AMPK and mTOR can function as sensors of metabolic
impairment, whose activation by energy stress controls
multiple cellular functions. Grahame Hardie (University of
Dundee, UK) and Reuben Shaw (Salk Institute, USA)
highlighted novel roles for AMPK, including inhibition of viral
replication, and the control of histone acetylation via
phosphorylation of class IIa HDACs, respectively. Brandon
Faubert (McGill University, USA) reported on an AMPK-
dependent effect on glucose metabolism in unstressed cells.
Brendan Manning (Harvard Medical School, USA) found that
chronic activation of mTOR in the mouse liver, due to genetic
ablation of this complex, promotes the development of liver
cancer. Kevin Williams (University of California, Los Angeles,
USA) discussed how growth signaling can control both lipid
and glucose metabolism by impinging on SREBP-1, a
transcription factor downstream of mTOR. AMPK-indepen-
dent control of mTOR was addressed by John Blenis
(Harvard Medical School, USA), who discussed the possible
role of mTOR stabilizing proteins as mediators of mTOR
inactivation upon energetic stress. David Sabatini (Whitehead
Institute/MIT, USA) discussed several aspects of amino-acid
sensing by Rag GTPases and showed that constitutive activa-
tion of the Rag GTPases leads to metabolic defects in mice.
One of the outcomes of AMPK activation and mTOR
inhibition is autophagy, which can provide amino acids and
fattyacidstonutrient-deprivedcells.AnaMariaCuervo(Albert
EinsteinCollegeofMedicine,USA)andEileenWhite(Rutgers
University, USA) illuminated the role of chaperone-mediated
autophagy (CMA) and macroautophagy, respectively, in
tumor survival. White described a role for macroautophagy
in the regulation of mitochondrial ﬁtness, maintenance
of TCA cycle and tumorigenesis induced by oncogenic Ras.
Cuervo described how CMA is consistently elevated
in tumor cells, and how its inactivation leads to metabolic
impairment via p53-mediated downregulation of glycolytic
enzymes.
Oncogene-speciﬁc changes to metabolism. Lewis
Cantley (Harvard Medical School, USA) described a meta-
bolic role for oncogenic Kras in the rewiring of glucose
metabolism in pancreatic cancer. Speciﬁcally, Myc-mediated
transcription (downstream of MEK-ERK signaling) both
enhances glucose uptake and diverts glucose carbon into
the nonoxidative pentose phosphate pathway to facilitate
nucleotide biosynthesis. Alejandro Sweet-Cordero (Stanford
University, USA) described how oncogenic Kras increases
glycolysis and represses mitochondrial respiration
(via decreased pyruvate dehydrogenase phosphatase 1
(PDP1) expression) in colon cancer. While these studies
indicate that hyperstimulation of the Erk pathway suppresses
PDH ﬂux through suppression of PDP1, Joan Brugge
(Harvard Medical School, USA) described studies showing
that reduction of Erk signaling in normal epithelial cells
also causes suppression of PDH ﬂux, in this case through
loss of repression of PDK4. The seemingly contradictory
nature of these results highlighted an important theme
emphasized throughout the week-long conference—that
cellular context has an important role in shaping
how oncogenic mutations or pathway activation rewires
metabolism.
Targeting cancer metabolism. There was extensive dis-
cussion around targeting metabolism for cancer therapy.
Metformin and phenformin, which act in part by mitochondrial
complex I inhibition, can activate AMPK and inﬂuence cancer
cell metabolism. Kevin Struhl (Harvard Medical School, USA)
described how metformin can selectively target cancer stem
cells, whereas Jessica Howell (Harvard Medical School,
USA) described how the therapeutic activity of metformin
relies on both AMPK and mTOR signaling to mediate its
effect. Similarly, David Shackelford (University of California,
Los Angeles, USA) demonstrated efﬁcacy for phenformin in
LKB1-deﬁcient mouse models.
Several presentations, including those by Taru Muranen
(Harvard Medical School, USA), Karen Vousden and Eyal
Gottlieb(bothfromtheBeatsonInstituteforCancerResearch,
UK), provided insight into genetic control mechanisms that
cancer cells use to promote survival under conditions of
increased biosynthesis. As an example, Vousden illustrated
how p53 loss can make cancer cells more dependent on
exogenous serine. Several additional presentations, including
those by Gottlieb, Richard Possemato (Whitehead Institute/
MIT, USA), Michael Pollak (McGill University, USA)
and Kevin Marks (Agios Pharmaceuticals, USA), also
included data highlighting the important role of serine
biosynthesis and metabolism in cancer growth. Collectively,
these data highlight a metabolic addiction that may be
therapeutically exploitable. Similarly, Cristina Mun ˜oz-Pinedo
(Institut d’Investigacio ´ Biome `dica, Spain) described how
mimicking glucose deprivation with 2-deoxyglucose can
cause programmed cell death and may be an effective
cancer treatment.
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Regulation of hypoxic responses. Peter Carmeliet
(University of Leuven, Belgium) highlighted the mechanisms
of resistance against VEGF-targeted therapies. Roland
Wenger (University of Zurich, Switzerland) discussed the
oxygen-responsive transcriptional networks and, in particu-
lar, the difference between the transcription factors HIF-1a
and HIF-2a. Importantly, he demonstrated a rapid role for
HIF-1a, and a later and more persistent response for HIF-2a.
These results were central to a recurrent theme calling for the
distinction of HIF-1a and HIF-2a target genes and how these
responses mediate divergent hypoxic adaptations.
Advances in hypoxic signaling. Brooke Emerling
(Harvard Medical School, USA) introduced CUB domain-
containing protein 1 (CDCP1) and showed persuasive data
on CDCP1 being a HIF-2a target gene involved in cell
migration and metastasis, and suggested CDCP1 regulation
as an attractive therapeutic target. Johannes Schodel
(University of Oxford, UK) described an elegant HIF-ChIP-
Seq methodology to deﬁne direct transcriptional targets of
HIF in renal cancer.
Randall Johnson (University of Cambridge, UK) empha-
sizedthat lossofHIF-1aresults in decreasedlungmetastasis.
Lorenz Poellinger (Karolinska Institutet, Sweden) focused on
how hypoxia can alter the epigenetic landscape of cells, and
furthermore, how the disruption of the histone demethylase
JMJD1A and/or the H3K9 methyltransferase G9a has oppos-
ing effects on tumor growth and HIF target gene expression.
Paul Schumacker (Northwestern University, USA) further
emphasized the importance of mitochondrial ROS signaling
underhypoxicconditionsshowingthatROScouldbedetected
in the inter-membrane space of the mitochondria before
activating signaling cascades in the cytosol. He also
presented evidence for mitochondria as a site of oxygen
sensing in diverse cell types. Similarly, Margaret Ashcroft
(University College London, UK) argued for a critical role of
mitochondria in hypoxic signaling. She presented on a family
of mitochondrial proteins (CHCHD4) that inﬂuence hypoxic
signaling and tumorigenesis and suggested that CHCHD4 is
important for HIF and tumor progression.
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